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Abstract MicroRNAs (miRNAs) are 20–22-nucleotide
small endogenous non-coding RNAs which regulate gene
expression at post-transcriptional level. In the last two
decades, identification of almost 2600 miRNAs in human
and their potential to be modulated opened a new avenue
to target almost all hallmarks of cancer. miRNAs have
been classified as tumor suppressors or oncogenes de-
pending on the phenotype they induce, the targets they
modulate, and the tissue where they function. miR-200c,
an illustrious tumor suppressor, is one of the highly stud-
ied miRNAs in terms of development, stemness, prolifer-
ation, epithelial-mesenchymal transition (EMT), therapy
resistance, and metastasis. In this review, we first focus
on the regulation of miR-200c expression and its role in
regulating EMT in a ZEB1/E-cadherin axis-dependent and
ZEB1/E-cadherin axis-independent manner. We then de-
scribe the role of miR-200c in therapy resistance in terms
of multidrug resistance, chemoresistance, targeted therapy
resistance, and radiotherapy resistance in various cancer
types. We highlight the importance of miR-200c at the
intersection of EMT and chemoresistance. Furthermore,
we show how miR-200c coordinates several important
signaling cascades such as TGF-β signaling, PI3K/Akt
signaling, Notch signaling, VEGF signaling, and NF-κB
signaling. Finally, we discuss miR-200c as a potential
prognostic/diagnostic biomarker in several diseases, but
mainly focusing on cancer and its potential application
in future therapeutics.
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Introduction
MicroRNAs (miRNAs), small non-coding RNAs that control
gene expression at post-transcriptional level, were discovered
only two decades ago, and their importance in cell biology is
exponentially increasing since then [1, 2]. Lin-4 gene, rather
than being translated into a protein, transcribed into a pair of
small RNAs (later termed as miRNAs) which imperfectly
base-paired to complementary sequences in the 3′-UTR of
different messenger RNAs (mRNAs), thus found to be in-
volved in post-transcriptional gene regulation. Later, the dis-
covery of the second miRNA, let-7 [3], and its sequence con-
servation across species from flies to human triggered seminal
follow-up works to unveil the basic concepts of miRNA bio-
genesis and function [4–6]. Over the period of the last
15 years, a total of more than 24,000 miRNA loci have been
discovered in 206 different species highlighting the potential
key regulatory functions of miRNAs in several organisms [7].
To date, miRNAs have been estimated to regulate more than
60 % of human genome [8] and dysregulated miRNA expres-
sion has been implicated in regulating various diseases and
developmental disorders. Moreover, the packed structure of
miRNAs led to their less vulnerability to degradation even
in serum environment [9] ensuring their suitability for diag-
nostic and therapeutic purposes [10–12]. miR-200c was first
shown to be dysregulated in several cancer cell lines [13].
Since then, miRNAs from miR-200 family, in general, but
miR-200c, in particular, have been explored to have an impact
on a large variety of biological processes and have been dem-
onstrated to play crucial roles in epithelial-mesenchymal
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transition (EMT), cell invasion, proliferation, metastasis, apo-
ptosis, autophagy, and therapy resistance in several cancer
types [14, 15]. There are more than 400 publications related
to miR-200c depicting the importance of this miRNA; thus,
the vast information about miR-200c deserves a compilation.
In this review, we focus on the molecular functioning of miR-
200c with special emphasis on regulation of EMT, cell inva-
sion, therapy resistance, role in signaling pathways, and its
potential as a biomarker in diverse diseases including cancer.
Regulation of miR-200c expression
miR-200 family is composed of two clusters: the miR-200a/b/
429 cluster containing miR-200a, miR-200b, and miR-429 on
chromosome 1p36 and the miR-200c/141 cluster containing
miR-200c and miR-141 on chromosome 12p13 (Fig. 1). In
addition to four enhancer boxes (E-box 1–4, CAGGTG), miR-
200c promoter has two specific sites (Z-box 1 and 2,
CAGGTA) restricted for the binding of ZEB transcription
factors [16]. ZEB1 alone or bound to different co-repressors
such as CtBPs and BRG1 suppresses miR-200c expression
[17, 18]. On the other hand, P300/PCAF complex can activate
miR-200c promoter via lysine acetylation of ZEB1 resulting
in the release of ZEB1 suppression on miR-200c/141 tran-
scription [19]. A study conducted on vMH neural progenitor
cells revealed Sox2 and E2F3 as additional transcription fac-
tors regulating transcription from the miR-200c/141 gene
cluster. Specific binding sites conserved across species (hu-
man, mouse, and rat) have been reported for Sox2 and E2F at
the distal (in the −1.4 to −1.3 kb region with respect to the
transcriptional start +1 of miR-200c/141 cluster) and proximal
promoter regions (−500 to −400 bp), respectively [20]. c-Myb
transcription factor also activates miR-200c gene through the
binding sites located in −1653 to −1647 bp and −988 to
−982 bp regions of the promoter [21]. Furthermore, the p53/
p63/p73 family of transcription factors has been reported
to positively regulate miR-200c expression in ovarian
cancer cells [22]. In mouse embryonic fibroblasts,
stemness-related transcription factor, Oct4, in combina-
tion with Sox2, has been implicated to serve as an activa-
tor of miR-200c gene expression [23].
Epigenetic gene regulatory mechanisms, such as DNA
methylation, are also capable of playing a predominant role
in regulating the expression of miR-200c (Fig. 1). For in-
stance, in breast cancer cells, miR-200c/141 cluster often un-
dergoes aberrant silencing due to methylation of CpG island
located in its promoter region [24]. In advanced stage bladder
cancer and poorly differentiated breast cancer cell lines, miR-
200 expression, along with miR-205, is found to be silenced
either due to promoter hypermethylation or due to direct bind-
ing of Twist transcriptional repressor on the promoter
[25]. Interestingly, miR-200c, itself, can indirectly act as
an epigenetic regulator. For example, ectopic expression
of miR-200b or miR-200c in mesenchymal breast cancer
cells resulted in partial upregulation of E-cadherin level
due to the degradation of ZEB1-histone deacetylase repressor
complexes and increase in the acetylation of histone H3 at the
E-cadherin promoter [26]. Overall, in addition to transcrip-
tional regulation of miR-200c, epigenetic mechanisms also
play a critical role in tuning miR-200c expression and in reg-
ulating its downstream effects.
Fig. 1 Regulation of miR-200c expression. Graphical depiction of chromosomal position of miR-200c/141 gene cluster, promoter and enhancer
sequences, and transcription factor binding sites
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Role of miR-200c in epithelial-mesenchymal
transition
EMT, defined as transformation of immotile epithelial
cells to motile and invasive mesenchymal cells by losing
their cell-to-cell adhesion properties [27], is a crucial step
in metastatic cascade. One of the hallmarks of EMT is
functional loss of cell surface marker E-cadherin and gain
of mesenchymal characteristics via elevating the levels of
mesenchymal proteins such as vimentin, fibronectin 1
(FN1), and N-cadherin [28]. Transcription factors associ-
ated with EMT, notably ZEB1 and ZEB2, suppress E-
cadherin expression and thus trigger the transformation
of epithelial cells into mesenchymal state and subsequent-
ly initiate the early steps of metastasis [29, 30].
miR-200c inhibits EMT via regulating
ZEB1/2/E-cadherin axis
miR-200 family members including miR-200c directly
target and repress ZEB1 and ZEB2 expression [31]
(Fig. 2), and their frequent loss with concomitant increase
in ZEB1 and ZEB2 expression has been observed in dif-
ferent cancers promoting EMT by downregulating E-
cadherin [16, 32, 33]. Conversely, ectopic expression of
E-cadherin in mesenchymal cells promotes the reverse
process and mesenchymal-epithelial transition, confirming
bona fide effects [31, 34]. For instance, via regulating
miR-200c in a feedback loop, ZEB1 contributes to harbor
stabilized EMT in invading cancer cells [16, 35].
Interestingly, miR-200c-ZEB1 interaction-mediated EMT
is also associated with acquisition of cancer stemness as
miR-200c suppresses cancer stem cell (CSC)-like features
by directly targeting ZEB1 as well as stem cell factors like
Bmi1, Sox2, and Klf4 [33, 36]. ZEB1 expression has been
shown to be high in embryonic stem (ES) cells, and the
expression of miR-200 family members is positively cor-
related with ESC differentiation [33, 35, 37].
Furthermore, the other factors involved in regulation of
miR-200c also hold significant importance in initiating
metastatic cascade. For instance, tumor suppressor tran-
scription factor, p53, has been demonstrated to suppress
EMT and EMT-related cancer stemness via provoking
transcriptional activation of miR-200c and associated
downregulation of ZEB transcription factors [38, 39]. In
addition, the C subunit of oncogenic mucin 1 (MUC1-C)
protein, which induces ZEB1 expression in a nuclear fac-
tor kappa B (NF-κB) p65-dependent manner, can
Fig. 2 miR-200c regulates EMT and drug resistance. Graphical representation of miR-200c-mediated regulation of EMTand drug resistance via direct
or indirect targeting of several proteins involved in EMT and multiple drug resistance mechanisms
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transcriptionally suppress miR-200c by forming a repres-
sion complex with ZEB1 and thus can regulate subse-
quent induction of EMT [40] (Fig. 2).
miR-200c inhibits EMT via regulating targets other than
ZEB1/2
Despite its importance, E-cadherin restoration is not always
enough for the inhibition of migration and invasion potential
of cancer cells; however, it has been shown that miR-200c
expression, alone, is enough to inhibit EMT, migration, and
invasion which suggests the involvement of other direct tar-
gets of miR-200c as EMT regulators [41]. A recent study has
suggested miR-200c-mediated repression of protein kinase A
subunits as the underlying mechanism of miR-200c-mediated
inhibition of migration in breast cancer cells [42]. This effect
of miR-200c has also been linked to its targeting of ubiquitin-
specific peptidase 25 (USP25) in non-small-cell lung cancer
(NSCLC) [43]. In addition, we have demonstrated that miR-
200c directly targets actin cytoskeleton regulatory proteins,
FHOD1 and PPM1F, and represses migration and invasion
of breast cancer cells in a ZEB1/2/E-cadherin-independent
manner [41]. Importantly, several molecules linked to cell
motility, such as FN1, moesin, neurotrophic tyrosine receptor
kinase type 2 (NTRK2 or TrkB), leptin receptor (LEPR), and
Rho GTPase-activating protein 19 (ARHGAP19), are among
the direct targets of miR-200c, and in aggressive breast and
endometrial cancer cells which lack miR-200c, aberrant ex-
pression of these targets contributes to the EMT phenotype
[44] (Fig. 2). Moreover, not only ZEB2 but also other proteins
in ZEB2 and Snail1 transcriptional repressor complexes such
as Crtap, FHOD1, Smad2, Map3k1, Tob1, Ywhag/14-3-3γ,
Ywhab/14-3-3β, Smad5, Zfp36, Xbp1 and Mapk12 are also
among the direct targets of miR-200c [45].
Cyclin-dependent kinase inhibitor, p21, is also capable
of blocking EMT [46] whereas loss of p21 induces EMT
and downregulates several miRNAs, including miR-200c,
in a colorectal cancer cell line. Interestingly, overexpres-
sion of miR-200c, alone, in these p21-deficient cells
inhibited EMT, migration, and invasion [47]. miR-200
family miRNAs are usually repressed in cells subjected
to EMT progression. For example, cells, which underwent
EMT in response to transforming growth factor beta
(TGF-β) or to ectopic expression of protein tyrosine
phosphatase, Pez, show decreased levels of miR-200 fam-
ily miRNAs [48]. Using a mouse model system, another
study has also shown that TGF-β-mediated EMT progres-
sion is indeed correlated with downregulation of miR-200
family miRNAs in mammary epithelial cells [34].
Overall, these studies suggest that both the regulation
and regulatory effects of miR-200c are critical determi-
nants in initiating EMT and pursuing the subsequent steps
in metastatic cascade.
Role of miR-200c in therapy resistance
In addition to regulation of EMT and metastasis, miR-200
family, in general, and miR-200c, in particular, also take part
in regulating therapy resistance. For instance, a recent study
with tissue samples from esophageal cancer patients receiving
neoadjuvant chemotherapy has clearly shown an inverse cor-
relation between miR-200c expression and sensitivity toward
chemotherapeutic agents. The underlying mechanism is pro-
posed to be enhanced activation of the PI3K/Akt pathway,
which is preceded by downregulation of a subunit of pro-
tein phophatase 2A, PPP2R1B, a negative regulator of
Akt phosphorylation. PPP2R1B is a direct target of
miR-200c; therefore, its downregulation through upregu-
lated miR-200c results in the activation of the PI3K/Akt
pathway and subsequent resistance against cisplatin [49]
(Fig. 2). In addition, higher levels of circulating miR-200c
have been observed in patients of castration-resistant
prostate cancer (CRPC), particularly, in those showing
resistance to docetaxel. Despite this seemingly negative
correlation between miR-200c levels and drug sensitivity
in patients, most of the in vitro studies suggest an oppo-
site link and present miR-200c as an inducer of sensitivity
against anti-cancer agents. This discrepancy may be due
to the influence of non-tumor cells on the levels of circu-
lating miR-200c as well as the regulatory effects of the
tumor microenvironment on cancer cells at the primary
tumor site [50]. Several targets of miR-200c are known
to play important roles in mediating multidrug resistance,
chemo-sensitivity and chemo-resistance, and targeted
therapy resistance as well as response to radiotherapy.
miR-200c and multidrug resistance
The role of miR-200c in multidrug resistance was first dem-
onstrated in relation to ATP-binding cassette (ABC) trans-
porters (Fig. 2), the largest transmembrane protein family,
responsible for resistance against multiple drugs. In general,
overexpression of ABC transporters creates increased drug
efflux, resulting in a decreased intracellular drug deposition
and a subsequent acquisition of resistance against the given
therapy [51]. miR-200c has been shown to play an active role
in limiting ABC transporter-mediated multidrug resistance in
melanoma as its ectopic expression in these cells was able to
downregulate ABC transporters: ABCG2, ABCG5, and
multi-drug resistance gene (MDR1). The underlying effect is
attributed to direct targeting of Bmi1 by miR-200c, and
knocking down Bmi1 in these cells results in lower ABC
transporter levels and higher sensitivity to a DNA-damaging
agent cisplatin, as well as to a BRAF and a MEK inhibitor
(PLX4720 and U0126, respectively) [52]. Being a member of
polycomb group proteins, Bmi1 is reported to be upregulated
in various cancers and is associated with a more aggressive
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disease progression and cancer stemness [53]. From these
findings, miR-200c seems to be an important player during
multidrug resistance considering the pivotal role of ABC
transporters in mediating chemoresistance in a wide variety
of cancers.
miR-200c and chemotherapy resistance
Overexpression of miR-200c has been shown to enhance the
response to several chemotherapeutic agents in various cancer
types. In melanoma cells, miR-200c overexpression results in
increased sensitivity to cisplatin [52] (Fig. 2). In endometrial
and ovarian cancers, miR-200c increases taxane sensitivity by
targeting class III B-tubulin gene (TUBB3), which is known
to be a mediator of resistance against microtubule-targeting
agents [54, 55]. A recent study, encompassing a panel of ovar-
ian adenocarcinoma cell lines, has also shown the inhibitory
action of miR-200c on TUBB3 expression, which also de-
pends on the nuclear localization of an RNA-binding protein,
HuR [56]. Another study revealed that decitabine treatment-
dependent upregulation of miR-200c and miR-141 promotes
epithelial-like characteristics in highly invasive oxaliplatin-
resistant colorectal cancer cells [57].
On the other hand, loss of miR-200c has been shown to be
associated with acquisition of resistance against various che-
motherapeutic agents in different cancer types. Doxorubicin
treatment of a breast cancer cell line, BT474, results in de-
creased miR-200c level, which ultimately leads to an increase
in KRAS, a direct target of miR-200c. This study suggests
miR-200c as an important checkpoint for the development
of chemoresistance mediated through activation of an impor-
tant oncogenic pathway [58]. In recurrent and metastatic co-
lorectal cancer, miR-200c expression is suppressed, and its
overexpression attenuates the JNK signaling pathway
resulting in an increased sensitivity of resistant cells to several
chemotherapeutic agents and a subsequent decrease in their
metastatic potential in both in vitro and in vivo models.
Furthermore, miR-200c level is inversely correlated with
JNK2, ABCB1, and MMP-9, which are the downstream tar-
gets of the JNK pathway, and this negative correlation may be
used as a predictive marker of therapeutic outcome in these
patients [59]. In two different breast cancer cell lines, resis-
tance against doxorubicin is correlated with marked inhibition
of miR-200c where TrkB has been suggested as the key target
of miR-200c in regulating this resistance [60]. TrkB plays
important roles in differentiation, in proliferation, and mostly,
in cell survival mediated through PLC, MAPK, or PI3K/Akt
signaling in neurons [61]. Notably, TrkB has also been found
to be associated with drug resistance in neuroblastoma [62,
63] and head and neck squamous cell carcinoma [64].
Interestingly, TrkB downregulation after ectopic expression
of miR-200c in doxorubicin-resistant breast cancer cells sen-
sitizes the cells toward doxorubicin treatment. Furthermore,
TrkB expression has been correlated with the phosphorylation
status of Akt in miR-200c-treated doxorubicin-resistant cells
where low p-Akt level has been observed with a concomitant
decrease in TrkB protein level [60]. All in all, these studies
propose possible mechanisms to explain the multi-factorial
nature of a given miRNA (here: miR-200c) in mediating the
response of cancer cells against different types of
chemotherapy.
miR-200c and targeted therapy resistance
Besides regulating chemotherapy resistance, miR-200c also
takes part in mediating targeted therapy resistance (Fig. 2).
In a microarray-based study on tamoxifen-sensitive MCF-7
and tamoxifen-resistant LY2 breast cancer cell lines, several
novel miRNAs including miR-200c were found to be differ-
entially expressed between sensitive and resistant cells [65]. In
a later study by the same group, it has been shown that ectopic
expression of miR-200c in endocrine-resistant LY2 cells has
significant effect on enhanced sensitivity to fulvestrant, but
not to tamoxifen [66]. Targeting the MAPK pathway is a
current treatment option for metastatic melanoma patients;
however, nearly 50 % of the patients receiving BRAF and
MEK inhibitors develop resistance within 6–7 months fol-
lowing treatment initiation. Overexpression of miR-200c
also significantly enhanced the anti-proliferative effects of
both PLX4720, a specific BRAF inhibitor, and trametinib,
a selective inhibitor of MEK1/2 kinase, in melanoma cells
[67] suggesting a potential anti-MAPK therapy sensitizer
role for miR-200c.
Reduced miR-200c and subsequent increase in its target
genes such as Bmi1, ZEB2, TUBB3, ABCG5, and MDR1
have also been shown to promote acquisition of BRAF inhib-
itor resistance in melanoma. Therefore, these genes could be
potential therapeutic targets against development of BRAF
inhibitor resistance [68]. In sorafenib- and imatinib-resistant
renal cell carcinoma cells, heme oxygenase 1 (HO1) has been
found to be a direct target of miR-200c. This enzyme is in-
duced during oxidative stress, and its overexpression follow-
ing a decrease in miR-200c level in resistant cells is found to
be partially responsible for drug resistance by inhibiting apo-
ptosis and autophagy [69]. Exploring druggable targets of
miR-200c responsible for conferring drug resistance may help
in shaping the strategies to improve the efficacy of chemother-
apy and targeted therapy.
miR-200c and radiotherapy resistance
The first line of evidence regarding association between miR-
200c and radiotherapy resistance came from a study on breast
cancer cells where low levels of miR-200c expression were
correlated with radio-tolerance, and ectopic miR-200c expres-
sion enhanced the (IR)-induced apoptosis by directly targeting
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TANK-binding kinase 1 (TBK1) [70] (Fig. 2). Recently, an-
other target of miR-200c, ubiquilin 1, has been shown to pos-
itively regulate radio-resistance by enhancing IR-induced au-
tophagy inMDA-MB-231 breast cancer cells. Ectopic expres-
sion of miR-200c reversed the phenotype and sensitized the
cells to radiation [71]. Furthermore, nanoparticle-assisted de-
livery of miR-200c has been shown to inhibit CSC-like prop-
erties and to augment radiosensitivity in three different gastric
cancer cell lines [72]. Altogether, miR-200c-assisted/conju-
gated therapies (chemotherapy, targeted therapy, and radio-
therapy) may have greater potential to overcome radiotherapy
resistance and to limit escape mechanisms in multiple cancer
types.
miR-200c at the intersection of EMTand drug
resistance
Over the last decade, several lines of evidence show that EMT
might render the cells resistant against the implemented anti-
cancer therapy supporting the notion that EMT and therapy
resistance go hand in hand [73]. In addition, involvement of
miRNAs in combined regulation of drug resistance and EMT
is evident [74]. Likewise, miR-200c, a negative regulator of
EMT, has shown great potential to overcome both chemother-
apy and targeted therapy resistance through reversing the
EMT process or promoting epithelial-like state (Fig. 2).
miR-200c, EMT, and chemotherapy resistance
Platinum-based chemotherapeutic agents, e.g., cisplatin, are
being used as first line treatment for NSCLC, but resistance
to these agents is inevitable. In highly aggressive cisplatin-
resistant NSCLC cells, miR-200c is lost due to promoter
hypermethylation, and forced introduction of miR-200c in-
duces loss of mesenchymal features, which reverses the resis-
tance against cisplatin [75]. In addition, upregulation of sev-
eral EMTmarkers including ZEB1/ZEB2 and downregulation
of epithelial marker, E-cadherin, are identified as the charac-
teristic features of docetaxel-resistant prostate cancer cells,
and the underlying mechanism again correlates with de-
creased miR-200c expression [76] (Fig. 2). Furthermore,
gemcitabine-resistant pancreatic cancer cells showed EMT
features along with low miR-200a, miR-200b, and miR-
200c levels. Upregulation of these miRNAs upon treatment
with two natural agents, 3,3′-diindolylmethane and isofla-
vone, reversed the EMT phenotype [77]. Moreover, the anti-
cancer effects of an anti-diabetic drug, metformin, have been
associated with downregulation of several CSC markers, such
as CD44 and EPCAM in pancreatic cancer, which, in turn,
linked with re-expression of several miRNAs including
miR-200c in gemcitabine-sensitive and gemcitabine -
resistant cells [78]. Similarly in pancreatic CSCs, decrease in
chemoresistance has been attributed to overexpression of
miR-200c [79]. In addition, miR-200c together with other
miRNAs from the miR-200 family has been shown to sensi-
tize ovarian cancer cell lines with strong EMT phenotype to
anti-cancer drugs paclitaxel and carboplatin [80].
A l though miR-200c-media t ed a t t enua t ion o f
chemoresistance is mainly associated with reversal of the
EMT process, underlying mechanisms are not restricted to
the canonical miR-200c/ZEB1/E-cadherin axis but involve
other miR-200c targets as well. For instance, in glioblastoma
cells, ectopic ZEB1 expression decreased the sensitivity to
chemotherapeutic agent, temozolomide (TMZ), in vitro while
ZEB1 knockdown resulted in opposite effects in both in vitro
and in vivo. ZEB1 was found to be co-localizing with a major
chemoresistance enzyme, MGMT, at the edges of glioblasto-
ma xenograft tumors where cells are more invasive and
chemoresistant. In principle, increased ZEB1 level in these
cells blocks miR-200c expression and subsequently
upregulates c-Myb transcription factor (a direct target of
miR-200c) which, in turn, activates MGMT transcription
resulting in attenuation of anti-proliferative effects of TMZ
[81]. Interestingly, a recent study on breast cancer lung metas-
tasis has shown that EMT is dispensable for lung metastasis,
but miR-200-mediated reversal of EMT helps in sensitizing
metastatic cells to chemotherapeutic drug cyclophosphamide
[82]. These results indicate the importance of miR-200c as a
key element in determining the fate of chemoresistant cancer
cell via regulating EMT.
miR-200c, EMT, and targeted therapy resistance
Association of miR-200c-mediated inhibition of EMT with
targeted therapy resistance has been established through sev-
eral studies. In particular, resistance against anti-EGFR thera-
pies (e.g., cetuximab, gefitinib, erlotinib, etc.) has been dem-
onstrated to be tightly linked with acquisition of EMT pheno-
types proceeded by the loss of miR-200c in various cancer
types. For instance, in urothelial carcinoma cells, showing
mesenchymal-like features and exhibiting resistance against
anti-EGFR therapies, a complete reversal of resistance could
be acquired with the introduction of miR-200c and subsequent
downregulation of ZEB1/2 and upregulation of E-cadherin
[83]. In gefitinib-resistant EGFR-mutant lung cancer cell
lines, low miR-200c expression due to DNA hypermethyla-
tion was found to be correlated with EMT features character-
ized by increased ZEB1 and decreased E-cadherin levels in
these cells [84]. Likewise, reversal of cetuximab resistance by
miR-200c is accompanied by the loss of EMT features in
highly invasive and aggressive NSCLC cells [75]. Similarly,
reversal of erlotinib resistance in EGFR-mutant NSCLC xe-
nografts treated with a potent natural agent, silibilin, is asso-
ciated with the loss of EMT-related features including low
miR-200c and E-cadherin and high ZEB1, Snail, and N-
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cadherin expression [85]. However, in a similar study with
erlotinib-resistant lung adenocarcinoma cells, overexpressed
miR-200c regulates expression of EMT network proteins
resulting in a slight increase in erlotinib sensitivity.
Furthermore, a TGF-β1-responsive element is identified at
the promoter region of miR-200c, which suggests the suppres-
sion of miR-200c in a Smad3/4-dependent manner at the
downstream of activated TGF-β signaling. Interestingly,
TGF-β1 is also not able to fully induce EMT and to cause
significant changes in erlotinib response in these cells [86].
Therefore, further understanding of the effects of TGF-β sig-
naling on miR-200c-mediated EMTand anti-EGFR resistance
could provide more details about the importance of the tumor
microenvironment in controlling miRNA expression and re-
sponse to targeted therapies.
Recently, a study in the context of the TGF-β/miR200c
axis explored that prolonged exposure to TGF-β not only
facilitates EMT but also makes cells undergo EMT-
associated kinase switch, which results in EGFR inhibitor re-
sistance characterized by decrease in miR-200c levels and
upregulation of one of its direct targets, Mig6/ERRFI-1.
Mig6 is a negative regulator of the EGFR family, and its
overexpression increases the internalization of EGFR and
thereby reduces its localization to the surface. Despite having
lower EGFR activation, cells overexpressing Mig6 show
higher Akt phosphorylation through activation of EGFR-
independent tyrosine kinases and thereby increase their sur-
vival. Furthermore, elevated Mig6/miR-200c ratio is found to
be associated with erlotinib resistance in a panel of 25 tumor
cell lines and in patient-derived xenografts (PDXs) of NSCLC
and pancreatic cancer [87]. Introduction of miR-200c to blad-
der cancer cells results in complete reversal of resistance
against anti-EGFR therapies mainly through Mig6 downreg-
ulation, which in turn leads to increased surface levels of EGF
receptors, thus making the anti-EGFR therapy more effective
in inhibiting the signal [83]. Recently, a feedback loop be-
tweenmiR-200c and TGF-β pathwaywas discovered in which
miR-200c can regulate TGF-β signaling by directly targeting
ZNF217, a transcriptional activator of autocrine TGF-β.
Elevated TGF-β signaling leads to increased invasiveness as
well as trastuzumab resistance (Fig. 2). In trastuzumab-
resistant breast cancer cells, miR-200c was found to be the
most significantly downregulated miRNA, and its ectopic ex-
pression decreases invasiveness and increases trastuzumab
sensitivity through downregulation of ZNF217. Besides
ZNF217, ZEB1 expression was also shown to be significantly
upregulated in trastuzumab-resistant cells. Double knock-
down of ZEB1 and ZNF217 decreased invasiveness and par-
tially restored trastuzumab sensitivity. Furthermore, miR-200c
treatment of xenografts of a trastuzumab-resistant breast can-
cer cell line leads to re-gain of trastuzumab sensitivity [88]. In
the same scenario, another level of regulation comes from a
long non-coding RNA, Lnc-ATB, which is expressed at the
downstream of TGF-β signaling and competitively binds to
miR-200c conferring ZEB1 and ZNF217 (upregulation)-me-
diated trastuzumab resistance [89]. In summary, these studies
clearly provide the cue that miR-200c could efficiently control
the response of cancer cells to anti-cancer therapies through
EMT-dependent and EMT-independent pathways.
miR-200c regulation of signaling pathways
Over the years, it has been well established that miR-200c
plays critical roles in regulating multiple biological processes
and signaling cascades varying from MAPK signaling, to
Notch signaling, to TLR signaling (Fig. 3). In the context of
developmental program, miR-200c has been found to accu-
mulate in epithelial buds in developing submandibular glands
and control FGFR-mediated epithelial proliferation by
targeting vldlr and its ligand reelin which regulate FGFR sig-
naling in these cells [90]. Furthermore, miR-200c-mediated
activation of BMP signaling via upregulation of amelogenin
and E-cadherin and via downregulation of noggins triggers
tooth development and renewal through dental epithelial cell
differentiation in mice [91].
IGF-induced PI3K/Akt and MAPK signaling can enhance
EMT and metastasis by downregulating miR-200c levels in
gastric cancer, which can be restored by Cbl-b-mediated
ubiquitination of IGF-IR [92] (Fig. 3). Recent data showed
that miR-200c negatively regulates KRAS as well, resulting
in inhibition of both PI3K/Akt and MAPK pathways in breast
and lung cancer cells [58, 93]. TGF-β-induced expression of
ZEB transcription factors downregulates miR-200c resulting
in reduced EGFR activity due to upregulation of Mig6 and
confers EMT [87]. On the contrary, TGF-β-induced upregu-
lation of miR-200c has been shown in diabetic nephropathy
where miR-200c targets FOG2, which is a negative regulator
of the PI3K/Akt pathway [94]. miR-200c also suppresses
TGF-β signaling by targeting ZNF217 in breast cancer cells,
an indirect mechanism to target ZEB-induced metastasis [88].
In addition to the well-characterized role of miR-200 fam-
ily miRNAs in the regulation of EMT, miR-200c has been
widely reported to take part in controlling tumor progression
either by regulating or being regulated by different signaling
mechanisms. Regarding cell death signaling, miR-200c sensi-
tizes breast cancer cells to aniokis by targeting NF-κB-
induced TrkB and NTF3 [44, 95] and enhances Fas-
associated apoptosis by targeting FAP-1 in different cancer
cell types [96] (Fig. 3). Additionally, in triple negative breast
cancer (TNBC), miR-200c has been shown to enhance apo-
ptosis by directly targeting X-linked inhibitor of apoptosis
(XIAP) which serves as E3 ubiquitin ligase and degrades
caspases essential for apoptosis [97]. In undifferentiated
human ESCs, miR-200c is upregulated, and its knock-
down downregulates Nanog expression and enhances
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GATA4 levels resulting in apoptosis [98]. Furthermore, Oct4
and Sox2 can bind to miR-200c promoter and enhance MET
and induce pluripotent stem cell development by suppressing
ZEB2 [23]. miR-200c was found to be downregulated in nor-
mal mammary progenitor cells and breast CSCs. When
overexpressed, it targets Bmi1, a known regulator of stem cell
self-renewal, and suppresses the mammary duct formation
ability of mammary stem cells and tumor growth driven by
breast CSC [36]. In colorectal cancer, miR-200c regulates
stemness by targeting Sox2 in a double negative feedback
loop, and loss of miR-200c resulted in enhanced expression
of stem cell markers (CD166, CD133, and beta-catenin)
downstream of Sox2. In the same study, miR-200c-Sox2 feed-
back loop has also been shown to regulate the PI3K/Akt path-
way and control the proliferative and metastatic potential of
colorectal cancer via phosphorylation of PI3K by Sox2 [99].
On the contrary, in pancreatic and ovarian cancer, miR-200c
has been shown to be directly targeting Zfpm2 and indirectly
reducing Pten levels, both of which are negative regulators of
the PI3K/Akt pathway [100, 101].
Notch signaling determines accurate growth and develop-
ment of various tissues and organs, and its aberrant activation
may lead to cancer. Overexpressing miR-200c in metastatic
prostate cancer impedes proliferative potential of cancer cells
by directly targeting Jagged1 receptors involved in Notch sig-
naling [102] whereas overexpression of Notch1 decreases
miR-200c levels in pancreatic cancer [103] (Fig. 3). Notch
also activates truncated isoform of Flt1/VEGFR-1 (which is
downregulated in the presence of miR-200c [104] and of im-
portance in angiogenesis-associated VEGF signaling) leading
to activation of proto-oncogene Src, which cross talks with
and downregulates miR-200c in an NF-κB/IL-6-dependent
manner [105]. miR-200c regulates TLR4/MyD88-dependent
activation of NF-κB by directly targeting MyD88.
Fig. 3 miR-200c in signaling pathways. Graphical representation of involvement of miR-200c in multiple signaling cascades and their cross-talk
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Interestingly, TAB2, TRAF6, and IRAK1, at the upstream of
NF-κB activation in TL4/MyD88 and TNF-α signaling, are
also among the potential targets of miR-200c depicting multi-
step targeting of signaling components by miRNAs [106]. In
breast cancer cells, MUC1-C induces EMT by upregulating
ZEB1 in an NF-κB/p65-dependent manner and downregulat-
ing miR-200c by making a complex with upregulated ZEB1
[40]. IL-6-mediated suppression of miR-200c led towards ac-
tivation of its downstream targets JNK2 and p65 (required for
constitutive activation of IL-6) whereas loss of IL-6 in a
mouse model impaired tumorigenicity due to activation of
miR-200c [107]. Overexpressing miR-200c also controls
inflammation-associated IL-8 in leiomyoma (smooth muscle
tumor) by targeting IKKB at the upstream of NF-κB, thus
decreasing p65 binding at IL-8 promoter [108]. Overall, in
addition to playing important roles in EMT and metastasis,
miR-200c has been adapted to regulate multiple normal
growth, development, cancer, and other diseases.
miR-200c as a biomarker
Similar to proteins, expression level of individual or group of
miRNAs has been suggested to be utilized as biomarkers to
predict disease progression, diagnosis, and treatment re-
sponse. In this scenario, dysregulated expression of miR-
200c in multiple cancer-related mechanisms, which we have
discussed here, is enough to support its use as a biomarker, at
least in cancer. miR-200c can both be (i) an intracellular mark-
er in tissues (cancer and normal) and (ii) an extracellular mark-
er in body fluids (blood, urine) as free molecules or secreted in
exosomes (Table 1).
As an intracellular marker, significantly downregulated
miR-200c together with downregulation of miR-335 and
miR-218 and upregulation of miR-122, miR-155, and miR-
210 has been anticipated to be used as a potential biomarker of
pathogenesis for clear cell renal cell cancer [120]. In addition,
miR-200c has been suggested as predictor of survival and
biomarker of relapse in stage I epithelial ovarian cancer pa-
tients [119]. In Caucasian and Asian intrahepatic
cholangiocellular carcinoma (ICC) patients, miR-200c down-
regulation resulted in enhanced EMT which led towards in-
creased cell motility and invasion capacity of ICC as well as
induced hepatic stem cell-like gene expression pattern, such as
NCAM1 upregulation [111]. In bladder cancer, low levels of
miR-200c along with miR-141 and miR-30b are associated
with poor prognosis [123]. In TNBC, reduced expression of
miR-200c along with miR-205 has been found to be signifi-
cantly associated with lymph node metastasis [124]. Recently,
it has been revealed that miR-200c levels are inversely corre-
lated with advanced clinical stages and lymph node metastasis
of ovarian cancer [47]. In intraductal papillary mucinous neo-
plasm (IPMN), the high-grade tumors were demonstrated to
have EMT characteristics such as low E-cadherin and high
vimentin and ZEB1 levels. Furthermore, miRNA array anal-
ysis identified miR-200c and miR-141 to be downregulated in
malignant tumors as compared to low-grade IPMN tumors.
This underpins the importance of the miR-200c-ZEB1 path-
way in the progression of IPMN and presents it not only as a
prognostic biomarker but also as a potential target for IPMN
therapy [113].
In addition to EMT and metastasis, miR-200c expression
has potential to predict therapy resistance as well. Ovarian and
breast cancer patients showing incomplete response to pacli-
taxel treatment expressed low levels of miR-200c along with
significant increase in beta-tubulin and ZEB1 expression
when compared with patients showing complete response to
paclitaxel [109, 118]. Furthermore, in NSCLC patients, high
expression of miR-200c has been found to be correlated with
bigger tumor size and worse overall survival suggesting an
oncogenic activity of miR-200c [114, 115]. In terms of tumor
subtype classification, oncocytoma and chromophobe struc-
tures in renal tumors can be distinguished according to miR-
200c and miR-139-5p expression patterns [121]. Moreover,
miR-200c together with differential expression of other
miRNAs is a candidate to distinguish hepatocellular carcino-
ma (HCC) from intrahepatic cholangiocarcinoma [112].
Besides its potential to be used as a biomarker in tis-
sues, miR-200c level in serum as circulating miRNA has
also been proven to be a promising prognostic and diag-
nostic factor for several diseases including various cancer
types. For instance, increased levels of circulating miR-
200 family members in serum have been shown to be
associated with serous epithelial ovarian cancer (SEOC)
[131] (Table 1). High level of miR-200c in sera of ovarian
[134] and esophageal cancer patients [135] is also corre-
lated with poor prognosis. Furthermore, presence of miR-
200c in patients’ sera as circulating miRNA has been val-
idated as a diagnostic marker for gastric cancer [127].
miR-200c has been shown as a significant predictor of
tumor stage in colorectal cancer as high level of this
miRNA in serum is able to significantly discriminate
stage IV from stage I–III colorectal cancer patients. In
addition, these high serum levels are positively correlated
with lymph node metastasis, distant metastasis, poor prog-
nosis, and tumor recurrence in colorectal cancer [125].
Similarly, in prostate cancer, together with four other cir-
culating miRNAs, elevated levels of miR-200c have been
shown to be higher in sera taken from patients with met-
astatic castration-resistant prostate cancer as compared to
healthy controls [132]. Dysregulated level of miR-200c in
serum has also been observed in non-cancer diseases such
as Crohn’s disease [126] and Kawasaki disease [128]
which further proves its fate as a diagnostic biomarker.
Circulating tumor cells (CTCs), on their own, are
shown to be indicators of cancer metastasis, but are
J Mol Med (2016) 94:629–644 637
difficult to detect [136]. Deep miRNA-array analysis of
circulating miRNAs in the sera of metastatic breast can-
cer patients and healthy controls has demonstrated that
miR-200c levels were significantly higher in CTC-
positive patients compared to CTC-negative patients
and healthy controls suggesting a role for circulating
miRNAs in predicting CTC status and associated meta-
static disease [50].
miRNAs are not only circulating in extracellular fluids,
but they are also secreted from tissues to their extracellu-
lar environment in exosomes. For instance, levels of miR-
200c and seven other miRNAs in tumor-secreted
exosomes were found to be similar to those in ovarian
tumor cells confirming diagnostic potential of profiling
circulating tumor exosomes [130]. Furthermore, exosomal
secretion of miR-200c in urine has been observed in var-
ious chronic kidney diseases [133] and in systemic dis-
eases such as lupus [137]. As a whole, miR-200c has a
huge potential to be used as a biomarker of diagnosis,
disease progression, and predicting treatment response.
Future perspectives
The role of miR-200 family, especially miR-200c, in regulat-
ing cancer metastasis and acquisition of drug resistance, two
major interlinked hallmarks of cancer, has been very well
established. However, a new insight came from a recent study
in breast cancer where miR-200 overexpression has been
shown not to affect onset of lung metastasis but to increase
post-metastatic chemosensitivity suggesting the potential of
miR-200-based EMT-targeting strategy in enhancing
chemosensitivity [82]. Further understanding of underlying
mechanisms will help improve and re-shape future EMT-
targeting strategies.
With the advances in the field of non-coding RNAs over
the last decade with the help of technological advancements in
deep sequencing, researchers have now started focusing on
the interactions among various kinds of non-coding RNAs,
e.g., long intergenic RNAs, circular RNAs and miRNAs,
etc., to understand the developmental and disease-associated
mechanisms. Recently, a long non-coding RNA named ATB
Table 1 miR-200c as a
biomarker Biomarker Disease Status Reference
Intracellular marker
Tissues Breast cancer Paclitaxel treatment response [109]
Colorectal cancer Metastasis [110]
ICC Diagnosis, subtype Classification,
EMT
[111, 112]
IPMN Malignancy, EMT [113]
Non-small cell lung cancer EMT, metastasis, Gemcitabine
drug response
[114–117]
Ovarian cancer Paclitaxel treatment response [118]
Epithelial ovarian cancer Patient survival [119]
Renal cell carcinoma Diagnosis, prognosis, metastasis,
subtype classification
[120–122]
Bladder cancer Prognosis [123]
CTCs Breast cancer Metastasis [124]
Extracellular marker
Serum Breast cancer Metastasis (via CTC) [50]
Colorectal cancer Prognosis, metastasis [125]
Crohn’s disease Diagnosis [126]
Gastric cancer Diagnosis, prognosis [127]
Kawasaki disease Diagnosis [128]
Lung cancer Prognosis [129]
Ovarian cancer Diagnosis (via exosomes) [130]
SEOC Diagnosis [131]
Prostate cancer Metastasis [132]
Urine Chronic kidney diseases Diagnosis (via exosomes) [133]
Diseases and their status related to miR-200c expression are listed with the location where significant miR-200c
expression has been detected to be used as a biomarker
ICC intrahepatic cholangiocarcinoma, IPMN intraductal papillary mucinous neoplasm, CTC circulating tumor
cells, SEOC serous epithelial ovarian cancer
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has been shown to be activated downstream of TGF-β, which
competitively binds to miR-200 family in HCC cells,
upregulates ZEB1/2 transcription factors, and induces EMT
[138]. Therefore, future research on miR-200c function
should also include lncRNAs, in addition to proteins, to have
a better understanding of its mechanism of action.
Importantly, cell-cell interaction via exosome transport
within the tumor microenvironment is of great importance in
maintaining tumor state and developing drug resistance. In
this line, pre-treatment of A549 cells with exosomes collected
from cisplatin-treated counterparts decreased miR-200c ex-
pression along with altering the expression of different
miRNAs [139]. Untangling the puzzles of the tumor microen-
vironment will further improve our knowledge about involve-
ment of miR-200c and its trafficking in regulating tumor state.
Tumor suppressor miRNAs, like miR-200c, have potential
to be used as therapeutic agents, but their delivery and stability
in body fluids is of great concern.Major challenges include (1)
poor penetration of miRNAs in tumor tissues, (2) miRNA
degradation in body fluids, (3) miRNA-associated
immunotoxicity and neurotoxicity, (4) inefficient gene silenc-
ing due to poor intracellular delivery ofmiRNAs, (5) off-target
effects, and (6) unavailability of sufficient miRNA-processing
enzymes. Multiple miRNA modification techniques have
been described to better overcome these barriers (reviewed
in [140]). For example, targeted delivery of aptamer-
conjugated let-7g in a xenograft model of lung adenocarcino-
ma has shown promising results in reducing tumor growth
[141]. In addition, combining miRNAs with other therapy
agents is another option to better utilize miRNAs as therapeu-
tic tool. For instance, miR-200c has been found to increase the
radiosensitivity by directly regulating oxidative stress re-
sponse genes PRDX2, GAPB/Nrf2, and SESN1 which led
to the inhibition of DNA double-strand break repair, increased
levels of reactive oxygen species, and upregulated p21 [142].
Recently, miR-34, a well-known tumor suppressor miRNA
that is in a double-negative feedback loop with Snail, like
miR-200c and ZEB1, has been entered in a phase-I clinical
trial (NCT01829971) for the treatment of HCC [143].
Furthermore, regarding the control of multiple oncogenes in
different tumor tissues, miR-200c can be considered as a
promising targeted therapy molecule similar to miR-34a.
Therefore, a broad range of tumor suppressor functions con-
ducted by miR-200c reviewed here also need to be assessed in
clinical trials for the benefit of patients using miR-200c-based
therapeutics.
Concluding remarks
Regulation of gene expression by miRNAs is not to serve just
as a switch—turning protein production on or off—but to
fine-tune the overall gene expression output providing
robustness to cell-specific programs. In this article, we
reviewed miR-200c, a well-established, exceptional miRNA,
which fine-tunes gene regulation in various diseases, especial-
ly in cancer. Notably, miR-200c simultaneously regulates ma-
jor elements of cancer progression, i.e., proliferation, EMT,
and drug resistance, in a context-dependent manner.
Commonly known mesenchymal transcription factors ZEB1
and ZEB2 are among the direct targets of miR-200c; thus, it
has established a strong link with EMT regulation. In
addition, miR-200c is also correlated with and regulates
chemoresistance, multidrug resistance, targeted therapy
resistance, radiotolerance, and stemness through targeting
and modulating the activities of key molecules involved
in these processes. Overall, miR-200c functions at the
crossroad of EMT and drug resistance reversal and has
great potential to be used as therapy sensitizer and bio-
marker for several cancer tissues due to its presence in
both intracellular as well as extracellular environment.
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